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The permutation tests were designed after Good. 1 The R scripts implementing these tests are available at the URL: https://doi.org/10.5281/zenodo.2684194
Independent-samples permutation test
We performed a permutation test on two independent antibody concentration sets x and y of size n and m to test the null hypothesis that the geometric mean concentrations (GMCs) are the same between the two groups of study participants. For this, we computed the difference of the respective GMCs, DGMC. Next, we compared this statistic against an empirical null distribution of the difference of GMCs that we generated by the Monte Carlo approach, as follows. We combined x and y into a single dataset (under the null hypothesis that the two sets of observations are identically distributed), drew a randomly-permuted dataset of size N = n + m by sampling the combined dataset without replacement, and split this permuted dataset into two subsets x' and y' of size n and m. We computed and recorded the difference of GMCs between x' and y', DGMC', and repeated the sampling and computation steps for B = 999999 total replications. Lastly, we computed a p-value by the formula:
where T denotes the number of cases in the permutation distribution where DGMC' ≥ DGMC in absolute value (two-tailed test).
Paired-samples permutation test
We performed a paired-samples permutation test to assess net changes in antibody concentrations between the first and second serum collections from the same study group of size n. Specifically, we tested the null hypothesis that the sum of differences between the paired concentrations equaled zero. We log-transformed the concentration data, and computed the sum of differences S across the n pairs of values. Next, we took the absolute value of each difference, gave it a plus or minus sign at random, and computed and recorded the sum of the n randomly-signed differences, S'. We repeated this step for B = 999999 total replications to build an empirical null distribution for the sum of differences. Lastly, we computed a p-value using equation (1) above with T as the number of cases in the permutation distribution where S' ≥ S in absolute value (two-tailed test).
Choice of the number of permutations B = 999999 was selected as sufficient to provide precision to three decimal digits when p = 0·05, i.e. such that the 95% confidence interval (CI) for the true p-value lie inside the interval [0·0495, 0·0505]. The bounds of the 95% CI for the true p-value were computed by the following formula after Ruxton and Neuhäuser, 2
where z(1 − 0·5a) denotes the (1 − 0·5a) quantile of the standard normal distribution (≈ 1·96 for a = 0·05), and p = 0·05.
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Appendix figure 1: Kernel density plot of the distributions of antibody concentrations. The figure compares the distributions of antibody concentrations between study groups and followup time points. The data correspond in each case to the combined seropositive and borderline strata. The dotted lines denote the seropositivity threshold (0·5 IU/ml), and the 1·8 IU/ml threshold between the low and high tiers of seropositives. p = 0·0075 p = 0·12 p = 0·28 p = 1 × 10 6 p 1 p = 0·20 p = 0·0081 p = 0·0087 Year-2·3 sera Total 
Appendix table 2: Statistics for seroreverters and late seroconverters in the Ghana cohort.
Seronegative denotes no read-out at the lowest dilution in the assay. Borderline, measurable antibody concentration <0·5 IU/ml. Seropositive, antibody concentration ≥0·5 IU/ml. Seroreversion denotes deterioration to the borderline or negative stratum; late seroconversion denotes amelioration of negative or borderline participants to the seropositive stratum 6 years postvaccination. The low and high tiers of seropositive participants are differentiated at the ≥1·8 IU/ml threshold. CI, confidence interval; GMC, geometric mean concentration; IQR, interquartile range; n.a., not applicable. 
